Preoperative serum C- reactive protein: A prognostic marker in patients with upper urinary tract urothelial carcinoma

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Stein, Barbara ^a   Schrader, Andres Jan ^b   Wegener, Gerd ^a   Seidel, Christoph ^a   Kuczyk, Markus A ^a   Steffens, Sandra ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF ULM MEDICAL SCHOOL   (Germany)

Author keywords

Aggressivness; Biomarker; C reactive protein; Prognosis; Survival; UUT UC

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; INVASIVE CARCINOMA; KIDNEY PELVIS CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUSCLE CANCER; PATIENT ASSESSMENT; PREOPERATIVE EVALUATION; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; VISCERAL METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; KIDNEY PELVIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREOPERATIVE PERIOD; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URETERAL NEOPLASMS;

EID: 84874515053     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-101     Document Type: Article

References (30)

1. Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol 2000, 164(5):1523-1525. 10.1016/S0022-5347(05)67019-X, 11025695.
2. Corrado F, Mannini D, Ferri C, Corrado G, Bertoni F, Bacchini P, Lieber MM, Song JM. The prognostic significance of DNA ploidy pattern in transitional cell cancer of the renal pelvis and ureter: continuing follow-up. Eur Urol 1992, 21(Suppl 1):48-50.
3. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998, 52(4):594-601. 10.1016/S0090-4295(98)00295-7, 9763077.
4. Kikuchi E, Horiguchi Y, Nakashima J, Hatakeyama N, Matsumoto M, Nishiyama T, Murai M. Lymphovascular invasion independently predicts increased disease specific survival in patients with transitional cell carcinoma of the upper urinary tract. J Urol 2005, 174(6):2120-2123. discussion 2124, 10.1097/01.ju.0000181801.22474.8b, 16280740.
5. Ozsahin M, Zouhair A, Villa S, Storme G, Chauvet B, Taussky D, Gouders D, Ries G, Bontemps P, Coucke PA. Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre Rare Cancer Network study. Eur J Cancer 1999, 35(5):738-743. 10.1016/S0959-8049(99)00012-X, 10505034.
6. Park S, Hong B, Kim CS, Ahn H. The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. J Urol 2004, 171(2 Pt 1):621-625.
7. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009, 27(13):2217-2224. 10.1200/JCO.2008.19.8440, 19289618.
8. McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 2006, 77(2):127-129. 10.1159/000093905, 16888416.
9. Iimura Y, Saito K, Fujii Y, Kumagai J, Kawakami S, Komai Y, Yonese J, Fukui I, Kihara K. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 2009, 181(3):1004-1012. discussion 1012, 10.1016/j.juro.2008.10.156, 19150550.
10. Kawata N, Nagane Y, Yamaguchi K, Ichinose T, Hirakata H, Takahashi S. How do symptoms have an impact on the prognosis of renal cell carcinoma?. Int J Urol 2008, 15(4):299-303. 10.1111/j.1442-2042.2008.01990.x, 18380815.
11. Komai Y, Saito K, Sakai K, Morimoto S. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 2007, 99(1):77-80. 10.1111/j.1464-410X.2006.06497.x, 16956357.
12. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 2006, 13(11):1365-1370. 10.1111/j.1442-2042.2006.01563.x, 17083384.
13. Jabs WJ, Busse M, Kruger S, Jocham D, Steinhoff J, Doehn C. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int 2005, 68(5):2103-2110. 10.1111/j.1523-1755.2005.00666.x, 16221209.
14. Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J, Patard JJ. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 2007, 110(6):1241-1247. 10.1002/cncr.22896, 17639589.
15. Lamb GW, McArdle PA, Ramsey S, McNichol AM, Edwards J, Aitchison M, McMillan DC. The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int 2008, 102(6):756-761. 10.1111/j.1464-410X.2008.07666.x, 18384626.
16. Ramsey S, Lamb GW, Aitchison M, McMillan DC. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int 2008, 101(8):959-963. 10.1111/j.1464-410X.2007.07363.x, 18190639.
17. Steffens S, Kohler A, Rudolph R, Eggers H, Seidel C, Janssen M, Wegener G, Schrader M, Kuczyk MA, Schrader AJ. Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer 2012, 12(1):399. 10.1186/1471-2407-12-399, 3502607, 22958305.
18. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006, 15(2):381-384. 10.1158/1055-9965.EPI-05-0626, 16492932.
19. Yoshida S, Saito K, Koga F, Yokoyama M, Kageyama Y, Masuda H, Kobayashi T, Kawakami S, Kihara K. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int 2008, 101(8):978-981. 10.1111/j.1464-410X.2007.07408.x, 18190628.
20. Saito K, Kawakami S, Ohtsuka Y, Fujii Y, Masuda H, Kumagai J, Kobayashi T, Kageyama Y, Kihara K. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int 2007, 100(2):269-273. 10.1111/j.1464-410X.2007.06934.x, 17488302.
21. Nakanishi H, Araki N, Kudawara I, Kuratsu S, Matsumine A, Mano M, Naka N, Myoui A, Ueda T, Yoshikawa H. Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma. Int J Cancer 2002, 99(2):167-170. 10.1002/ijc.10343, 11979429.
22. Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF, McArdle CS. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005, 92(4):651-654. 10.1038/sj.bjc.6602419, 2361875, 15700032.
23. Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res 2004, 30(3):261-277. 10.1385/IR:30:3:261, 15531769.
24. Maccio A, Lai P, Santona MC, Pagliara L, Melis GB, Mantovani G. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol 1998, 69(3):248-252. 10.1006/gyno.1998.4974, 9648596.
25. Matsumoto K, Kinoshita T, Ishida T, Itoh H, Miki C, Suzuki H. Serum levels of NCC-ST-439 in Dukes' C colorectal cancer patients: a preliminary report. Surg Today 1999, 29(1):91-92. 10.1007/BF02482979, 9934841.
26. McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer 2004, 91(12):1993-1995. 10.1038/sj.bjc.6602248, 2410147, 15570310.
27. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995, 55(20):4633-4639.
28. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989, 250(2):607-610. 10.1016/0014-5793(89)80805-1, 2787758.
29. Takenawa J, Kaneko Y, Fukumoto M, Fukatsu A, Hirano T, Fukuyama H, Nakayama H, Fujita J, Yoshida O. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst 1991, 83(22):1668-1672. 10.1093/jnci/83.22.1668, 1749019.
30. Okamoto M, Hattori K, Oyasu R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 1997, 72(1):149-154. 10.1002/(SICI)1097-0215(19970703)72:1<149::AID-IJC21>3.0.CO;2-D, 9212236.